Emerging therapeutics in the management of connective tissue disease. Part I. Lupus erythematosus and Sjögren syndrome

Skudalski, Lauren; Shahriari, Neda; Torre, Kristin; Santiago, Sueheidi; Bibb, Lorin A; Kodomudi, Vijay; Grant‐Kels, Jane M.; Lu, Jun

doi:10.1016/j.jaad.2021.12.067

Cited by 3 publications

(1 citation statement)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…But the results of a subgroup analysis indicated the potential effectiveness of filgotinib in patients with severe disease activity and with no concomitant medications. [ 121 ] More clinical trials of the safety and efficacy of tofacitinib (NCT04496960) and baricitinib (NCT05016297) in patients with pSS are in progress in the US and China [ 122 ] [Table 2 ].…”

Section: Role Of Jak-stat Signaling Pathway In Treatment Of Pssmentioning

confidence: 99%

Role of JAK-STAT signaling pathway in pathogenesis and treatment of primary Sjögren's syndrome

Lin

et al. 2023

Chinese Medical Journal

View full text Add to dashboard Cite

Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease with high prevalence and possible poor prognosis. Though the pathogenesis of pSS has not been fully elucidated, B cell hyperactivity is considered as one of the fundamental abnormalities in pSS patients. It has long been identified that Janus kinases-signal transducer and activator of transcription (JAK-STAT) signaling pathway contributes to rheumatoid arthritis and systemic lupus erythematosus. Recently, increasing numbers of studies have provided evidence that JAK-STAT pathway also has an important role in the pathogenesis of pSS via direct or indirect activation of B cells. Signal transducer and activator of transcription 1 (STAT1), STAT3, and STAT5 activated by various cytokines and ribonucleic acid contribute to pSS development, respectively or synergically. These results reveal the potential application of Janus kinase inhibitors for treatment of pSS, which may fundamentally improve the quality of life and prognosis of patients with pSS.

show abstract

Section: Role Of Jak-stat Signaling Pathway In Treatment Of Pssmentioning

confidence: 99%

Role of JAK-STAT signaling pathway in pathogenesis and treatment of primary Sjögren's syndrome

Lin

et al. 2023

Chinese Medical Journal

View full text Add to dashboard Cite

show abstract

A comprehensive analysis of type 1 interferon gene signatures in systematic lupus erythematosus and prediction of the crucial susceptible factor for Sjögren syndrome

Mi,

Lai,

Yan

et al. 2023

Clin Exp Med

View full text Add to dashboard Cite

Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions

et al. 2023

View full text Add to dashboard Cite

Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs; keratinocytes, cytotoxic T cells and plasmacytoid dendritic cells (pDCs) establish a self-perpetuating interplay between the innate and adaptive immune system that is pivotal for the pathogenesis of CLE. Therefore, treatment relies on avoidance of triggers and UV protection, topical therapies (glucocorticosteroids, calcineurin inhibitors) and rather unspecific immunosuppressive or immunomodulatory drugs. Yet, the advent of licensed targeted therapies for SLE might also open new perspectives in the management of CLE. The heterogeneity of CLE might be attributable to individual variables and we speculate that the prevailing inflammatory signature defined by either T cells, B cells, pDCs, a strong lesional type I interferon (IFN) response, or combinations of the above might be suitable to predict therapeutic response to targeted treatment. Therefore, pretherapeutic histological assessment of the inflammatory infiltrate could stratify patients with refractory CLE for T-cell-directed therapies (e.g. dapirolizumab pegol), B-cell-directed therapies (e.g. belimumab), pDC-directed therapies (e.g. litifilimab) or IFN-directed therapies (e.g. anifrolumab). Moreover, Janus kinase (JAK) and spleen tyrosine kinase (SYK) inhibitors might broaden the therapeutic armamentarium in the near future. A close interdisciplinary exchange with rheumatologists and nephrologists is mandatory for optimal treatment of lupus patients to define the best therapeutic strategy.

show abstract

Emerging therapeutics in the management of connective tissue disease. Part I. Lupus erythematosus and Sjögren syndrome

Cited by 3 publications

References 92 publications

Role of JAK-STAT signaling pathway in pathogenesis and treatment of primary Sjögren's syndrome

Role of JAK-STAT signaling pathway in pathogenesis and treatment of primary Sjögren's syndrome

A comprehensive analysis of type 1 interferon gene signatures in systematic lupus erythematosus and prediction of the crucial susceptible factor for Sjögren syndrome

Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions

Contact Info

Product

Resources

About